BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Liponex, Inc. and ImaSight Update Status of Proposed Business Combination


6/4/2008 2:56:01 PM

OTTAWA, BURLINGTON, MISSISSAUGA, ON, and MONTREAL and GATINEAU, QC, May 28 /PRNewswire-FirstCall/ - Liponex Inc. and ImaSight Inc., a commercial stage medical device company marketing an innovative, cost effective digital radiology solution, today updated the status of the proposed transaction to combine their respective businesses that was announced on March 3, 2008.

Liponex has today filed on SEDAR the information circular being mailed to its shareholders in respect of its Annual and Special Meeting of the shareholders being held on June 20, 2008. In addition, the parties have received the conditional acceptance of the TSX Venture Exchange of the listing of the shares of the issuer resulting from the proposed business combination, subject to among other things the approval of the Liponex shareholders at the Annual and Special Meeting and receipt of final documentation.

Completion of the proposed transaction remains subject to the fulfillment or waiver of various conditions precedent as more particularly set forth in the acquisition agreement, including the receipt of all required third party consents and all required shareholder approvals and regulatory approvals. We cannot assure you that the transaction will be completed as proposed or at all.

About ImaSight and its Digital Radiography System

ImaSight markets its patented digital x-ray sensor at a price affordable to veterinarians and chiropractors. Its hospital grade sensor has been approved for sale by Health Canada. Further information can be found at www.imasight.com

About Liponex and CRD5

Liponex is a Biopharmaceutical development company developing natural source products for the treatment of cholesterol and metabolic disease. CRD5, its lead product, has undergone a number of human clinical trials under approval of Health Canada's Natural Health Products Directorate with a primary goal of increasing HDL "good cholesterol".

This news release contains certain "forward-looking statements" and "forward-looking information" which may include but is not limited to statements in respect of the proposed business combination between Liponex and ImaSight. Words like "believe", "intend", "may", "expect", "anticipate", "plan", "should", "assume" and other similar expressions are forward-looking statements that involve a number of risks and uncertainties. By their nature, forward-looking statements involve numerous factors, assumptions and estimates. Some but not all of the factors that could cause actual results to differ materially from those projected in our forward-looking statements include among others:

For a further description of the principal risks affecting Liponex, see Liponex's regulatory filings at www.sedar.com. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward looking statements. Although Liponex and ImaSight have attempted to identify important risks, uncertainties and other factors that could cause actual results or events to differ materially from those expressed or implied in the forward looking statements, there may be other factors that cause actual results or events to differ from those expressed or implied in the forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and neither Liponex nor ImaSight undertakes no obligation to revise or update any forward-looking statements as a result of new information, future events or otherwise after the date hereof.

CONTACT: Liponex Inc.: William Dickie, President and Chief Executive
Officer, (613) 274-7809 ext. 200, Bdickie@liponex.ca; ImaSight Inc.: John
Brooks, CEO, (819) 777-7979 ext. 223, jbrooks@imasight.com


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->